Literature DB >> 14519539

Antioxidant activity of X-34 in synaptosomal and neuronal systems.

Jaroslaw Kanski1, Rukhsana Sultana, William Klunk, D Allan Butterfield.   

Abstract

Inhibiting aggregation and deposition of amyloid beta-peptide (Abeta) in brain is a therapeutic strategy for Alzheimer's disease (AD). A Congo-red-like molecule, X-34, is reported to bind to Abeta deposits. Oxidative stress associated with Abeta is hypothesized to be critical for the neurotoxic properties of this peptide. The present study was undertaken to test the hypothesis that X-34, with its salicylate groups, would act as an antioxidant. When challenged by hydroxyl or peroxyl free radicals or Abeta(1-42), oxidative stress and neurotoxicity occurred in neural systems as assessed by several indices. However, pretreatment of synaptosomes and primary neuronal cell culture with X-34 greatly ameliorated lipid peroxidation induced by these free radicals and Abeta(1-42). Protein oxidation was not prevented by X-34. These results are discussed in terms of potential therapeutic use of X-34 and related compounds in AD.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14519539     DOI: 10.1016/s0006-8993(03)03369-9

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  2 in total

1.  Anti-Amyloid Effects of Small Molecule Aβ-Binding Agents in PS1/APP Mice.

Authors:  A D Cohen; M D Ikonomovic; E E Abrahamson; W R Paljug; S T Dekosky; I M Lefterov; R P Koldamova; L Shao; M L Debnath; N S Mason; C A Mathis; W E Klunk
Journal:  Lett Drug Des Discov       Date:  2009-09       Impact factor: 1.150

2.  Pharmacological characterization of memoquin, a multi-target compound for the treatment of Alzheimer's disease.

Authors:  Valeria Capurro; Perrine Busquet; Joao Pedro Lopes; Rosalia Bertorelli; Glauco Tarozzo; Maria Laura Bolognesi; Daniele Piomelli; Angelo Reggiani; Andrea Cavalli
Journal:  PLoS One       Date:  2013-02-18       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.